The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Open accessAbstract
Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge. High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12
REED, L. J., & MUENCH, H. (1938) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a118408 · Cited by 19,926
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Emergence of Zaire Ebola Virus Disease in Guinea
Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M. S., Keïta, S., De Clerck, H., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404505 · Cited by 1,366
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Epitopes Involved in Antibody-Mediated Protection from Ebola Virus
Wilson, J. A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A. L., & Hart, M. K. (2000) · Science · doi:10.1126/science.287.5458.1664 · Cited by 459
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., Colebunders, R., Muyembe‐Tamfum, J. J., & the International Scientific and Technical Committee (1999) · The Journal of Infectious Diseases · doi:10.1086/514298 · Cited by 420
Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V., & Gleba, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606631103 · Cited by 419
Geisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Self-citationSuccessful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies
Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., Strong, J. E., Plummer, F., Corbett, C. R., Alimonti, J. B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003876 · Cited by 315
Self-citationPathogenesis of Experimental Ebola Virus Infection in Guinea Pigs
Connolly, B. M., Steele, K. E., Davis, K. J., Geisbert, T. W., Kell, W. M., Jaax, N. K., & Jahrling, P. B. (1999) · The Journal of Infectious Diseases · doi:10.1086/514305 · Cited by 308
Effective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Self-citationJahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200409109 · Cited by 268
Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M., Hiatt, A., Ngo, L., Steinkellner, H., Whaley, K. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108360108 · Cited by 229
Self-citationAdvanced antisense therapies for postexposure protection against lethal filovirus infections
Warren, T. K., Warfield, K. L., Wells, J., Swenson, D. L., Donner, K. S., Van Tongeren, S. A., Garza, N. L., Dong, L., Mourich, D. V., Crumley, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2202 · Cited by 203
Wong, G., Richardson, J. S., Pillet, S., Patel, A. R., Qiu, X., Alimonti, J. B., Hogan, J., Zhang, Y., Takada, A., Feldmann, H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004582 · Cited by 160
Self-citationRecombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever
Hensley, L. E., Stevens, E. L., Yan, S.-C. B., Geisbert, J. B., Macias, W. L., Larsen, T., Daddario-DiCaprio, K. M., Cassell, G. H., Jahrling, P. B., & Geisbert, T. W. (2007) · The Journal of Infectious Diseases · doi:10.1086/520598 · Cited by 157
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
Qiu, X., Alimonti, J. B., Melito, P. L., Fernando, L., Ströher, U., & Jones, S. M. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.08.008 · Cited by 127
Self-citationQiu, X., Audet, J., Wong, G., Fernando, L., Bello, A., Pillet, S., Alimonti, J. B., & Kobinger, G. P. (2013) · Scientific Reports · doi:10.1038/srep03365 · Cited by 106
Self-citationQiu, X., Fernando, L., Melito, P. L., Audet, J., Feldmann, H., Kobinger, G., Alimonti, J. B., & Jones, S. M. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001575 · Cited by 98
Self-citationBausch, D. G., Sprecher, A., Jeffs, B., & Boumandouki, P. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2008.01.152 · Cited by 94
Clinical Management of Filovirus-Infected Patients
Clark, D. V., Jahrling, P. B., & Lawler, J. V. (2012) · Viruses · doi:10.3390/v4091668 · Cited by 78
Cited by
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
“Thus, the use of a mixture of antibodies, including some directed against non-RBD epitopes, is a preferred strategy (29) and has been used successfully for the treatment of Ebola virus disease (30).”
MethodBiopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
Menachery, V. D., Yount, B. L., Debbink, K., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X.-Y., Donaldson, E. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901
Metadata
- Authors
- Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., Johnson, A., Morton, J., Swope, K., Bohorov, O., Bohorova, N., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Pettitt, J., Olinger, G. G., Whaley, K., Xu, B., Strong, J. E., Zeitlin, L., & Kobinger, G. P.
- Venue
- Nature
- Published
- 2014-08-29
- Volume
- 514
- Issue
- 7520
- Pages
- 47-53
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2094993149
- Cited by
- 987
- References
- 23
- FWCI
- 108.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.